MDT-AP-0731
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 48.96
- os_event
- false
- age_years
- 0.91
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.638425076
- umap2_2d
- -8.516903747
- umap1_3d
- -4.094335062
- umap2_3d
- -2.110957831
- umap3_3d
- 6.215927172
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.560
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.480
- INFLAMMATORY_RESPONSE+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- UV_RESPONSE_DN+0.380
- TGF_BETA_SIGNALING+0.370
- COMPLEMENT+0.360
- ANDROGEN_RESPONSE+0.350
Top 10 suppressed
- DNA_REPAIR-0.210
- KRAS_SIGNALING_DN-0.170
- APICAL_SURFACE-0.150
- HEME_METABOLISM-0.100
- SPERMATOGENESIS-0.070
- PANCREAS_BETA_CELLS-0.050
- FATTY_ACID_METABOLISM-0.030
- OXIDATIVE_PHOSPHORYLATION+0.030
- HEDGEHOG_SIGNALING+0.040
- MYOGENESIS+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934750 | — | — | 0.906 |
| 2 | SRR934866 | — | — | 0.904 |
| 3 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.903 |
| 4 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.896 |
| 5 | SRR934807 | — | — | 0.896 |
| 6 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.891 |
| 7 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.891 |
| 8 | C6888F62-AE14-4F73-A1B8-2CB81E2809FD | — | — | 0.890 |
| 9 | SRR934842 | — | — | 0.889 |
| 10 | SRR934816 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |